fda approval bpc 157 status BREAKING: The just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC-157 2. Thymosin beta-4 fragment (TB-500) 3. Epitalon 4. GHK-Cu (injectable) ghk-cu fda approval status 2026
Description
A groundbreaking 2025 study investigated Long COVID patients suffering from persistent "visuoconstructive deficits"severe cognitive impairments related to spatial and visual processing
GHK-Cu creates new blood vessels and addresses inflammation
Most evidence remains preclinical, with limited controlled human research currently available
Treatment typically requires intramuscular hydroxocobalamin injections (1 mg three times weekly initially, then every 23 months lifelong) when malabsorption or neurological symptoms are present
Is BPC-157 effective for sports injuries
